Table 1 Baseline characteristics analysis
From: Plasma Galectin-3 is associated with progression from paroxysmal to persistent atrial fibrillation
Variables | Progressed (51) | Not-progressed (162) | p value |
|---|---|---|---|
Age | 71.7 ± 1.7 | 66.9 ± 0.8 | 0.005 |
BMI, kg/m2 | 24.9 ± 0.5 | 25.4 ± 0.3 | 0.456 |
Male | 33 (64.7%) | 84 (51.5%) | 0.068 |
Hypertension | 36 (70.6%) | 114 (69.9%) | 0.539 |
Diabetes mellitus | 16 (31.4%) | 48 (29.5%) | 0.461 |
Stroke | 9 (17.7%) | 12 (7.4%) | 0.035 |
COPD | 2 (3.9%) | 1 (0.6%) | 0.081 |
CAD | 23 (45.1%) | 56 (34.6%) | 0.175 |
eGFR,mL/(min·1.73m2) | 85.5 ± 4.58 | 86.1 ± 1.26 | 0.854 |
LAD,mm | 41.3 ± 0.90 | 39.3 ± 0.39 | 0.021 |
LVEF,% | 64.6 ± 1.19 | 64.6 ± 0.71 | 0.984 |
Gal-3,ng/ml | 13.5 ± 0.94 | 7.9 ± 0.37 | < 0.001 |
NT-proBNP,pg/ml | 1488.6 ± 339.19 | 551.1 ± 81.85 | < 0.001 |
hs-CRP,mg/ml | 1.6 (0.92,4.70) | 1.5 (0.91,3.36) | 0.347 |
ACEI/ARB | 23 (45.1%) | 71 (43.6%) | 0.486 |
Stains | 32 (62.8%) | 114 (69.9%) | 0.213 |
β‐blocker | 26 (51.0%) | 81 (49.7%) | 0.500 |
rhythm control | 36 (70.6%) | 134 (82.7%) | 0.072 |
Ablation | 33 (64.7%) | 126 (77.8%) | 0.061 |
AAD | 3 (5.9%) | 8 (4.9%) | 0.790 |